May 03, 2016 10:39 PM ET

Biotechnology

Company Overview of aTyr Pharma Inc.

Company Overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and clinical development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare genetic myopathy with an immune component; patients with early onset FSHD; and adult patients with limb-girdle muscular dystrophy 2B or FSHD. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory domain program. The company was founded in 2005 and is headquartered in San Diego, California.

3545 John Hopkins Court

Suite 250

San Diego, CA 92121

United States

Founded in 2005

55 Employees

Phone:

858-731-8389

Fax:

858-731-8394

Key Executives for aTyr Pharma Inc.

Chief Executive Officer and Director
Age: 55
Total Annual Compensation: $472.8K
Vice President of Clinical Affairs
Age: 51
Total Annual Compensation: $295.0K
Senior Advisor
Age: 57
Total Annual Compensation: $291.2K
Compensation as of Fiscal Year 2015.

aTyr Pharma Inc. Key Developments

aTyr Pharma, Inc. Announces Encouraging Phase 1b/2 Results for Resolaris in First Rare Myopathy Trial

aTyr Pharma Inc. announced results from a Phase 1b/2 clinical trial evaluating Resolaris in adult FSHD (facioscapulohumeral muscular dystrophy) patients. The company is developing Resolaris, a potential first-in-class protein therapeutic, for the treatment of rare myopathies with an immune component (RMICs). The Phase 1b/2 study was designed to evaluate the safety, tolerability, immunogenicity and pharmacokinetic (PK) profile of Resolaris in adult FSHD patients, the Company's first treated RMIC population. In addition, the study also evaluated the utility of exploratory pharmacodynamic (PD) markers (including MRI measurements to quantitate areas of potential muscle inflammation) and clinical assessments (including patient reported outcomes). In this randomized, double-blind, placebo-controlled trial, Resolaris was studied in three dose escalation cohorts (0.3, 1.0, and 3.0 mg/kg) across four sites and 20 patients. In each cohort, patients were randomized at a ratio of 3:1 to receive Resolaris or placebo. Patients in the first two dose cohorts were dosed weekly over a period of one month, and patients in the third cohort were dosed weekly over a period of three months. As planned, the company enrolled a total of four patients in the first cohort and eight patients in each of the second and third cohorts. For the second and third cohorts, inclusion criteria included the presence of at least one skeletal muscle in the legs identified by a non-quantitative MRI technique, which is thought to indicate inflammation. The analysis is based on data available through early March 2016.

aTyr Pharma Inc. Appoints Sanjay Shukla as Chief Medical Officer

aTyr Pharma Inc. announced that Sanjay Shukla, MD, MS, has joined the company as Chief Medical Officer. Dr. Shukla will lead aTyr's clinical efforts to advance its Physiocrine biology therapeutic intervention points and strategically develop meaningful medicines that promote tissue homeostasis for patients with various severe and rare diseases. In Dr. Shukla's most recent role as Vice President and Global Head of Integrated Medical Services for Novartis.

aTyr Pharma Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015

aTyr Pharma Inc. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2015. For the quarter, the company announced loss from operations of $16,483,000 compared to $6,030,000 for the same period a year ago. Net loss was $16,493,000 compared to $6,038,000 for the same period a year ago. Net loss attributable to common stockholders was $16,493,000 compared to $6,038,000 for the same period a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.70 compared to $7.04 for the same period a year ago. For the year, the company announced loss from operations of $47,616,000 compared to $23,554,000 for the same period a year ago. Net loss was $47,973,000 compared to $24,350,000 for the same period a year ago. Net loss attributable to common stockholders was $47,988,000 compared to $24,766,000 for the same period a year ago. Net loss per share attributable to common stockholders, basic and diluted was $3.03 compared to $29.69 for the same period a year ago.

Similar Private Companies By Industry

Company Name Region
VM Pharma LLC United States
Gene 24 United States
Motif BioSciences, Inc. United States
Recros Medica, Inc. United States
MuciMed, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact aTyr Pharma Inc., please visit www.atyrpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.